Latest News & Updates

Featured

September 15, 2026

June 18, 2026

UBS Private Biotech Summit Highlights Tenvie Therapeutics: First NLRP3 biomarker data in Q4 to support CNS-penetrant obesity/CV thesis

News

April 20, 2026

Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV108, an Allosteric SARM1 inhibitor

News

April 6, 2026

Tenvie Therapeutics Announces Dosing of First Subject in Phase 1 Clinical Trial of TNV262, a Fully CNS-Penetrant NLRP3 Inhibitor

All News

Keep up to date with the world of TENVIE

News 08/Jan/2025

Tenvie Therapeutics Launches with $200 Million to Deliver Breakthrough Small Molecule Therapies

Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases Led by expert R&D leadership team with proven ability to develop therapies for CNS and peripheral diseases ARCH Venture Partners, F-Prime Capital, and Mubadala Capital lead $200 million investment to fuel acceleration of Tenvie into a multi-clinical asset company SOUTH SAN FRANCISCO, January […]